{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T18:10:40Z","timestamp":1777227040868,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jns.2021.120056","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T10:46:19Z","timestamp":1636627579000},"page":"120056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Out with the old, in with the new: Could plasma exchange be used to fill a therapeutic gap in neurology?"],"prefix":"10.1016","volume":"432","author":[{"given":"Jonathan I.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximillian","family":"Crane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex D.","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele C.","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.120056_bb0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fncel.2018.00072","article-title":"An inflammation-centric view of neurological disease: beyond the neuron","volume":"12","author":"Skaper","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jns.2021.120056_bb0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jns.2021.120056_bb0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/practneurol-2019-002336","article-title":"Plasma exchange in neurological disease","volume":"20","author":"Osman","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0025","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/bmj.1.4763.854","article-title":"Use of plasmapheresis in blood donors","volume":"1","author":"Grifols-Lucas","year":"1952","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jns.2021.120056_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the writing Committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jns.2021.120056_bb0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/tme.12205","article-title":"Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products","volume":"25","author":"Howell","year":"2015","journal-title":"Transfus. Med."},{"key":"10.1016\/j.jns.2021.120056_bb0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jca.21331","article-title":"Neurologic indications for therapeutic plasma exchange: 2013 update","volume":"29","author":"Gwathmey","year":"2014","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.jns.2021.120056_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-brain barrier: from physiology to disease and Back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jns.2021.120056_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0271678X16679420","article-title":"Age-associated physiological and pathological changes at the blood-brain barrier: a review","volume":"37","author":"Erd\u0151","year":"2017","journal-title":"J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jns.2021.120056_bb0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41582-020-00421-4","article-title":"Towards treating progressive multiple sclerosis","volume":"16","author":"Thompson","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0060","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0065","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000011275","article-title":"Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses","volume":"96","author":"Benedict","year":"2021","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2021.120056_bb0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","article-title":"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial","volume":"19","author":"Chataway","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0075","first-page":"7","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.120056_bb0080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.39.9.1143","article-title":"Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis","volume":"39","author":"Weiner","year":"1989","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2021.120056_bb0085","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1212\/WNL.35.3.312","article-title":"Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs","volume":"35","author":"Khatri","year":"1985","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2021.120056_bb0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.41.3.409","article-title":"Plasma exchange in chronic progressive multiple sclerosis: a long-term study","volume":"41","author":"Khatri","year":"1991","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2021.120056_bb0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","volume":"337","year":"1991","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jns.2021.120056_bb0105","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1212\/WNL.46.6.1620","article-title":"Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study","volume":"46","author":"S\u00f8rensen","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2021.120056_bb0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jnnp-2017-316011","article-title":"Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier","volume":"89","author":"Spencer","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.120056_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrn.2018.13","article-title":"Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics","volume":"19","author":"Petersen","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2021.120056_bb0120","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1093\/brain\/awm236","article-title":"Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?","volume":"130","author":"Marik","year":"2007","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.24997","article-title":"Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex","volume":"82","author":"Yates","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1084\/jem.20061931","article-title":"The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease","volume":"204","author":"Adams","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2021.120056_bb0135","first-page":"2428","article-title":"Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats","volume":"35","author":"Paterson","year":"1976","journal-title":"Fed. Proc."},{"key":"10.1016\/j.jns.2021.120056_bb0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000367682","article-title":"Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two","volume":"38","author":"Z\u00f6llner","year":"2014","journal-title":"Blood Purif."},{"key":"10.1016\/j.jns.2021.120056_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.2003.033324","article-title":"Sex hormones modulate brain damage in multiple sclerosis: MRI evidence","volume":"76","author":"Tomassini","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.120056_bb0150","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ana.24807","article-title":"Prothrombin and factor X are elevated in multiple sclerosis patients","volume":"80","author":"G\u00f6bel","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2249.2008.03830.x","article-title":"Complement in multiple sclerosis: its role in disease and potential as a biomarker","volume":"155","author":"Ingram","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jns.2021.120056_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128952","article-title":"Plasma biomarkers discriminate clinical forms of multiple sclerosis","volume":"10","author":"Tejera-Alhambra","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2021.120056_bb0165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathol. (Berl.)."},{"key":"10.1016\/j.jns.2021.120056_bb0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"10.1016\/j.jns.2021.120056_bb0175","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA."},{"key":"10.1016\/j.jns.2021.120056_bb0180","series-title":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug","author":"O. of the Commissioner","year":"2021"},{"key":"10.1016\/j.jns.2021.120056_bb0185","article-title":"Perspective: is therapeutic plasma exchange a viable option for treating Alzheimer\u2019s disease?","volume":"6","author":"Imbimbo","year":"2020","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.jns.2021.120056_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.652111","article-title":"Dysregulation of systemic immunity in aging and dementia","volume":"15","author":"Lutshumba","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jns.2021.120056_bb0195","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nm.3569","article-title":"Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice","volume":"20","author":"Villeda","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2021.120056_bb0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10357","article-title":"The ageing systemic milieu negatively regulates neurogenesis and cognitive function","volume":"477","author":"Villeda","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.jns.2021.120056_bb0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamaneurol.2018.3288","article-title":"Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study: a randomized clinical trial","volume":"76","author":"Sha","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0210","series-title":"Important Information about Young Donor Plasma Infusions for Profit","author":"C. for B.E. and Research","year":"2019"},{"key":"10.1016\/j.jns.2021.120056_bb0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","article-title":"Plasma exchange for Alzheimer\u2019s disease management by albumin replacement (AMBAR) trial: study design and progress","volume":"5","author":"Boada","year":"2019","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.jns.2021.120056_bb0220","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-160565","article-title":"Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-\u03b2 concentrations and cognition outcomes in Alzheimer\u2019s disease patients: a multicenter, randomized, controlled clinical trial","volume":"56","author":"Boada","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2021.120056_bb0225","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/alz.12137","article-title":"A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: primary results of the AMBAR study","volume":"16","author":"Boada","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2021.120056_bb0230","first-page":"163","article-title":"Sink hypothesis and therapeutic strategies for attenuating Abeta levels","volume":"17","author":"Zhang","year":"2011","journal-title":"Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry"},{"key":"10.1016\/j.jns.2021.120056_bb0235","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-a beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer\u2019s disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2021.120056_bb0240","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-beta by circulating lipoprotein receptors","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2021.120056_bb0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/JAD-2010-101248","article-title":"Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-\u03b2 is an early biomarker for mild cognitive impairment preceding Alzheimer\u2019s disease","volume":"24","author":"Sagare","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2021.120056_bb0250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fncel.2021.695479","article-title":"Relationship between amyloid-\u03b2 deposition and blood\u2013brain barrier dysfunction in Alzheimer\u2019s disease","volume":"15","author":"Wang","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jns.2021.120056_bb0255","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/187152709787601867","article-title":"Clearance of amyloid-\u03b2 peptide across the blood-brain barrier: implication for therapies in Alzheimer\u2019s disease","volume":"8","author":"Deane","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jns.2021.120056_bb0260","doi-asserted-by":"crossref","first-page":"15154","DOI":"10.1074\/jbc.M112.439570","article-title":"A lipoprotein receptor cluster IV mutant preferentially binds amyloid-\u03b2 and regulates its clearance from the mouse brain","volume":"288","author":"Sagare","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2021.120056_bb0265","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1084\/jem.20181035","article-title":"3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice","volume":"216","author":"Lazic","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2021.120056_bb0270","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/JAD-2011-101977","article-title":"Meta-analysis of plasma amyloid-\u03b2 levels in Alzheimer\u2019s disease","volume":"26","author":"Song","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2021.120056_bb0275","doi-asserted-by":"crossref","DOI":"10.1177\/2050312115598250","article-title":"A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer\u2019s disease","volume":"3","author":"Shanthi","year":"2015","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.jns.2021.120056_bb0280","unstructured":"Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease | NEJM, (n.d.). https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1812840 (accessed O1ctober 18, 2021)."},{"key":"10.1016\/j.jns.2021.120056_bb0285","unstructured":"Target Engagement in an Alzheimer Trial: Crenezumab Lowers Amyloid \u03b2 Oligomers in Cerebrospinal Fluid - Yang - 2019 - Annals of Neurology - Wiley Online Library, (n.d.). https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ana.25513 (accessed October 18, 2021)."},{"key":"10.1016\/j.jns.2021.120056_bb0290","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3233\/JAD-210011","article-title":"Safety and tolerability of GRF6019 infusions in severe Alzheimer\u2019s disease: a phase II double-blind placebo-controlled trial","volume":"81","author":"Hannestad","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2021.120056_bb0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12883-017-0865-7","article-title":"Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0300","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.025","article-title":"Correlation between fibrinogen and white matter hyperintensities among nondiabetic individuals with noncardiogenic ischemic stroke","volume":"27","author":"You","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.jns.2021.120056_bb0305","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2015-05-646117","article-title":"Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation","volume":"127","author":"Shen","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.jns.2021.120056_bb0310","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1089\/neu.2017.5291","article-title":"Contribution of fibrinogen to inflammation and neuronal density in human traumatic brain injury","volume":"35","author":"Jenkins","year":"2018","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.jns.2021.120056_bb0315","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000260970.63493.c8","article-title":"Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide","volume":"68","author":"Greenberg","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2021.120056_bb0320","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.seizure.2012.09.011","article-title":"Plasma exchange in cryptogenic new onset refractory status epilepticus","volume":"22","author":"Li","year":"2013","journal-title":"Seizure."},{"key":"10.1016\/j.jns.2021.120056_bb0325","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/practneurol-2011-000084","article-title":"Seronegative limbic encephalitis: case report, literature review and proposed treatment algorithm","volume":"11","author":"Ahmad","year":"2011","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2021.120056_bb0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WNN.0b013e318190d195","article-title":"Successful treatment of acute autoimmune limbic encephalitis with negative VGKC and NMDAR antibodies","volume":"22","author":"Modoni","year":"2009","journal-title":"Cogn. Behav. Neurol. Off. J. Soc. Behav. Cogn. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:35Z","timestamp":1758383975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":66,"alternative-id":["S0022510X21027581"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120056","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Out with the old, in with the new: Could plasma exchange be used to fill a therapeutic gap in neurology?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120056"}}